• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Looking Ahead: A Conversation Surrounding Closing the Gaps in Plaque Psoriasis Management


Drs Lisa Swanson and Robert J. Casquejo express their optimism for the future of plaque psoriasis management, sharing their vision for expanded treatment approvals in the pediatric population affected by this condition.

This is a video synopsis/summary of a panel discussion involving Lisa Swanson, MD, FAAD, and Robert J. Casquejo, PA-C.

In this discussion, dermatologists explore the future prospects of phosphodiesterase-4 (PDE-4) inhibitors, focusing on apremilast. One dermatologist expresses excitement about the ongoing study, SPROUT, which investigates apremilast in pediatric patients aged 6 to 17 years. They discuss the potential approval of this medication for children, highlighting its oral form as a preferable alternative to injections.

The conversation delves into the broader applications of PDE-4 inhibitors, expressing interest in exploring their efficacy in various dermatological conditions beyond psoriasis. They specifically mention observations suggesting a potential role in decreasing neutrophilic recruitment, raising the possibility of addressing diseases like neutrophilic dermatoses.

The dermatologists then shift to discussing persistent treatment gaps in psoriasis management. They highlight the need to address mild psoriasis more aggressively with systemic medications, emphasizing the discrepancy between objective analysis and subjective patient experiences. They advocate for increased awareness and data highlighting the impact of mild psoriasis on patients' lives, challenging the perception of mild disease by both healthcare providers and patients.

Additionally, they identify gaps in pediatric systemic therapies for psoriasis, expressing the desire for more options beyond the existing 4 approved medications. The discussion extends to the importance of long-term studies assessing the impact of systemic therapy on reducing comorbidities associated with psoriasis. They cite studies suggesting a potential decrease in all-cause mortality and hope for more research to establish systemic treatments as beneficial beyond managing skin symptoms.

Overall, the dermatologists express enthusiasm for the future possibilities of PDE-4 inhibitors, emphasizing their potential in pediatric populations and their broader applications in various dermatological conditions. They advocate for a more comprehensive approach to psoriasis management, addressing treatment gaps and exploring systemic therapies' long-term benefits on comorbidities.

Video synopsis is AI-generated and reviewed by DermatologyTimes editorial staff.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.